Citations (107)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Parag Roy, Nimmy Kumari, Noopur Pandey, Abhishek Gour, Amit Raj, B. Srividya, Utpal Nandi & Animesh Ghosh. (2022) Development of ezetimibe eutectic with improved biopharmaceutical and mechanical properties to design an optimized oral solid dosage formulation. Pharmaceutical Development and Technology 27:10, pages 989-998.
Read now
Read now
Ya-Bin Ma, Paul Chan, Yuzhen Zhang, Brian Tomlinson & Zhongmin Liu. (2019) Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia. Expert Opinion on Pharmacotherapy 20:8, pages 917-928.
Read now
Read now
Harold E Bays. (2014) Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus. International Journal of General Medicine 7, pages 355-364.
Read now
Read now
Linda Dayer-Berenson, Mary Finckenor & Michelle Tuzzolino. (2014) Are add-on agents to statin therapy necessary in hypercholesterolemia?. Clinical Lipidology 9:6, pages 695-707.
Read now
Read now
JoAnne M Foody, Peter P Toth, Andrew M Tershakovec, Thomas Musliner, Joanne E Tomassini, Robert S Lowe, David R Neff & Harry R Davis. (2014) Efficacy and safety of ezetimibe plus atorvastatin therapy. Clinical Lipidology 9:4, pages 441-470.
Read now
Read now
Jun Liu, Yuan-Lin Guo, Rui-Xia Xu & Jian-Jun Li. (2013) Rapid effects of different lipid-lowering drugs on PCSK9 in humans. Clinical Lipidology 8:5, pages 519-524.
Read now
Read now
Julian P Halcox. (2013) Cardiovascular risk and lipid management beyond statin therapy: the potential role of omega–3 polyunsaturated fatty acid ethyl esters. Clinical Lipidology 8:3, pages 329-344.
Read now
Read now
Alberico Catapano, Peter P Toth, Joanne E Tomassini & Andrew M Tershakovec. (2013) The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups. Clinical Lipidology 8:1, pages 13-41.
Read now
Read now
Sheila A Doggrell. (2012) The ezetimibe controversy – can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together?. Expert Opinion on Pharmacotherapy 13:10, pages 1469-1480.
Read now
Read now
Peter P Toth, Alberico Catapano, Joanne E Tomassini & Andrew M Tershakovec. (2010) Update on the efficacy and safety of combination ezetimibe plus statin therapy. Clinical Lipidology 5:5, pages 655-684.
Read now
Read now
Fernanda Luisa Ceragioli Oliveira, Rose Vega Patin & Maria Arlete Meil Schimith Escrivão. (2010) Atherosclerosis prevention and treatment in children and adolescents. Expert Review of Cardiovascular Therapy 8:4, pages 513-528.
Read now
Read now
Harold Bays. (2009) Review of ARBITER 2: Extended-Release Niacin Added to Statin Therapy Slows the Progression of Atherosclerosis. Postgraduate Medicine 121:2, pages 195-198.
Read now
Read now
Irina A Pikuleva. (2008) Cholesterol-metabolizing cytochromes P450: implications for cholesterol lowering. Expert Opinion on Drug Metabolism & Toxicology 4:11, pages 1403-1414.
Read now
Read now
AJ Taylor, LE Sullenberger, HJ Lee, JK Lee & KA Grace. (2008) Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. The Physician and Sportsmedicine 36:1, pages 129-131.
Read now
Read now
Articles from other publishers (93)
Zhentao Zhang, Qi Zhang, Yiwen Zhang, Yutao Lou, Luqi Ge, Wanli Zhang, Wen Zhang, Feifeng Song & Ping Huang. (2024) Role of sodium taurocholate cotransporting polypeptide (NTCP) in HBV-induced hepatitis: Opportunities for developing novel therapeutics. Biochemical Pharmacology 219, pages 115956.
Crossref
Crossref
Martina Parente, Claudia Tonini, Marco Segatto & Valentina Pallottini. (2023) Regulation of cholesterol metabolism: New players for an old physiological process. Journal of Cellular Biochemistry 124:10, pages 1449-1465.
Crossref
Crossref
Alena M. Bubeck, Paul Urbain, Cathrine Horn, Anna S. Jung, Lisa Ferrari, Hannah K. Ruple, Daniel Podlesny, Stefanie Zorn, Johnny Laupsa-Borge, Caroline Jensen, Inge Lindseth, Gülen Arslan Lied, Jutta Dierkes, Gunnar Mellgren, Hartmut Bertz, Silke Matysik, Sabrina Krautbauer, Gerhard Liebisch, Hans-Frieder Schoett, Simon N. Dankel & W. Florian Fricke. (2023) High-fat diet impact on intestinal cholesterol conversion by the microbiota and serum cholesterol levels. iScience 26:9, pages 107697.
Crossref
Crossref
Arezoo Rajabian, Alice P. McCloskey, Tannaz Jamialahmadi, Seyed Adel Moallem & Amirhossein Sahebkar. (2023) A review on the efficacy and safety of lipid-lowering drugs in neurodegenerative disease. Reviews in the Neurosciences 0:0.
Crossref
Crossref
Rasha E Mostafa & Rehab F Abdel-Rahman. (2023) Ezetimibe alleviates acetic acid-induced ulcerative colitis in rats: targeting the Akt/NF-κB/STAT3/CXCL10 signaling axis. Journal of Pharmacy and Pharmacology 75:4, pages 533-543.
Crossref
Crossref
Eric M. Brown, Jon Clardy & Ramnik J. Xavier. (2023) Gut microbiome lipid metabolism and its impact on host physiology. Cell Host & Microbe 31:2, pages 173-186.
Crossref
Crossref
Harold Edward Bays. 2023. Lipoproteins in Diabetes Mellitus. Lipoproteins in Diabetes Mellitus
705
734
.
Yan Li, Jun Zhou & Tianliang Li. (2022) Regulation of the HBV Entry Receptor NTCP and its Potential in Hepatitis B Treatment. Frontiers in Molecular Biosciences 9.
Crossref
Crossref
Momoko Matsuyama, Keiji Hirai, Hiroaki Nonaka, Moeka Ueda, Junki Morino, Shohei Kaneko, Saori Minato, Yuko Mutsuyoshi, Katsunori Yanai, Hiroki Ishii, Taisuke Kitano, Akinori Aomatsu, Haruhisa Miyazawa, Kiyonori Ito, Yuichiro Ueda, Susumu Ookawara & Yoshiyuki Morishita. (2022) Effects of Elobixibat on Constipation and Lipid Metabolism in Patients With Moderate to End-Stage Chronic Kidney Disease. Frontiers in Medicine 8.
Crossref
Crossref
Rishab Marahatha, Saroj Basnet, Bibek Raj Bhattarai, Prakriti Budhathoki, Babita Aryal, Bikash Adhikari, Ganesh Lamichhane, Darbin Kumar Poudel & Niranjan Parajuli. (2021) Potential natural inhibitors of xanthine oxidase and HMG-CoA reductase in cholesterol regulation: in silico analysis. BMC Complementary Medicine and Therapies 21:1.
Crossref
Crossref
Jessica Frigerio, Erik Tedesco, Federico Benetti, Violetta Insolia, Giovanna Nicotra, Valerio Mezzasalma, Stefania Pagliari, Massimo Labra & Luca Campone. (2021) Anticholesterolemic Activity of Three Vegetal Extracts (Artichoke, Caigua, and Fenugreek) and Their Unique Blend. Frontiers in Pharmacology 12.
Crossref
Crossref
Andrea Poli, Franca Marangoni, Alberto Corsini, Enzo Manzato, Walter Marrocco, Daniela Martini, Gerardo Medea & Francesco Visioli. (2021) Phytosterols, Cholesterol Control, and Cardiovascular Disease. Nutrients 13:8, pages 2810.
Crossref
Crossref
Teruo Jojima, Shintaro Sakurai, Sho Wakamatsu, Toshie Iijima, Masahiro Saito, Takuya Tomaru, Takahiko Kogai, Isao Usui & Yoshimasa Aso. (2021) Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol. International Journal of Cardiology 331, pages 243-248.
Crossref
Crossref
Takanari Nakano, Ikuo Inoue, Yasuhiro Takenaka, Rina Ito, Norihiro Kotani, Sawako Sato, Yuka Nakano, Masataka Hirasaki, Akira Shimada & Takayuki Murakoshi. (2020) Ezetimibe impairs transcellular lipid trafficking and induces large lipid droplet formation in intestinal absorptive epithelial cells. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1865:12, pages 158808.
Crossref
Crossref
Douglas J. Kenny, Damian R. Plichta, Dmitry Shungin, Nitzan Koppel, A. Brantley Hall, Beverly Fu, Ramachandran S. Vasan, Stanley Y. Shaw, Hera Vlamakis, Emily P. Balskus & Ramnik J. Xavier. (2020) Cholesterol Metabolism by Uncultured Human Gut Bacteria Influences Host Cholesterol Level. Cell Host & Microbe 28:2, pages 245-257.e6.
Crossref
Crossref
Peter P. Toth, Harold E. Bays, W. Virgil Brown, Alberico L. Catapano, Michael H. Davidson, Michel Farnier, Joanne E. Tomassini, Erin Jensen, Adam B. Polis & Andrew M. Tershakovec. (2019) Comparing remnant lipoprotein cholesterol measurement methods to evaluate efficacy of ezetimibe/statin vs statin therapy. Journal of Clinical Lipidology 13:6, pages 997-1007.e8.
Crossref
Crossref
Linda L. DemerJeffrey J. HsuYin Tintut. (2018) Steroid Hormone Vitamin D. Circulation Research 122:11, pages 1576-1585.
Crossref
Crossref
Menizibeya Osain WelcomeMenizibeya Osain Welcome. 2018. Gastrointestinal Physiology. Gastrointestinal Physiology
871
972
.
Mona Mohammed El-Tamalawy, Osama Mohamed Ibrahim, Timour Mostafa Hassan & Ali Ali El-Barbari. (2018) Effect of Combination Therapy of Ezetimibe and Atorvastatin on Remnant Lipoprotein Versus Double Atorvastatin Dose in Egyptian Diabetic Patients. The Journal of Clinical Pharmacology 58:1, pages 34-41.
Crossref
Crossref
Peter Fraunberger, Elisabeth Gröne, Hermann-Josef Gröne, Heinz Drexel & Autar K. Walli. (2017) Ezetimibe reduces cholesterol content and NF-kappaB activation in liver but not in intestinal tissue in guinea pigs. Journal of Inflammation 14:1.
Crossref
Crossref
Vanessa H. Quinlivan & Steven A. Farber. (2017) Lipid Uptake, Metabolism, and Transport in the Larval Zebrafish. Frontiers in Endocrinology 8.
Crossref
Crossref
Jen-Chieh Chuang, Adam M. Lopez & Stephen D. Turley. (2017) Quantitation of the rates of hepatic and intestinal cholesterol synthesis in lysosomal acid lipase-deficient mice before and during treatment with ezetimibe. Biochemical Pharmacology 135, pages 116-125.
Crossref
Crossref
Si Van Nguyen, Takamitsu Nakamura, Manabu Uematsu, Daisuke Fujioka, Kazuhiro Watanabe, Yosuke Watanabe, Jun-ei Obata, Kazuto Nakamura & Kiyotaka Kugiyama. (2017) Remnant lipoproteinemia predicts cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Journal of Cardiology 69:3, pages 529-535.
Crossref
Crossref
Lukáš Dobiaš, Monika Laššánová & Viera Kristová. (2016) Hypolipidemic drugs and their effect on endothelial function: a review of results of clinical trials. Klinická farmakologie a farmacie 30:2, pages 38-45.
Crossref
Crossref
Auryan Szalat, Ronen Durst & Eran Leitersdorf. (2016) Managing dyslipidaemia in type 2 diabetes mellitus. Best Practice & Research Clinical Endocrinology & Metabolism 30:3, pages 431-444.
Crossref
Crossref
Gouda K. Helal, Magdy A. Gad, Mohamed F. Abd-Ellah & Elsayed M. Mahgoup. (2016) Coadministration of ezetimibe with pegylated interferon plus ribavirin could improve early virological response in chronic hepatitis C obese Egyptian patients. European Journal of Gastroenterology & Hepatology 28:5, pages 553-557.
Crossref
Crossref
Harold Bays, Shanu N. Kothari, Dan E. Azagury, John M. Morton, Ninh T. Nguyen, Peter H. Jones, Terry A. Jacobson, David E. Cohen, Carl Orringer, Eric C. Westman, Deborah B. Horn, Wendy Scinta & Craig Primack. (2016) Lipids and bariatric procedures Part 2 of 2: scientific statement from the American Society for Metabolic and Bariatric Surgery (ASMBS), the National Lipid Association (NLA), and Obesity Medicine Association (OMA). Surgery for Obesity and Related Diseases 12:3, pages 468-495.
Crossref
Crossref
Harold E. Bays, Peter H. Jones, Terry A. Jacobson, David E. Cohen, Carl E. Orringer, Shanu Kothari, Dan E. Azagury, John Morton, Ninh T. Nguyen, Eric C. Westman, Deborah B. Horn, Wendy Scinta & Craig Primack. (2016) Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: EXECUTIVE SUMMARY. Journal of Clinical Lipidology 10:1, pages 15-32.
Crossref
Crossref
Harold E. Bays, Peter H. Jones, Terry A. Jacobson, David E. Cohen, Carl E. Orringer, Shanu Kothari, Dan E. Azagury, John Morton, Ninh T. Nguyen, Eric C. Westman, Deborah B. Horn, Wendy Scinta & Craig Primack. (2016) Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: FULL REPORT. Journal of Clinical Lipidology 10:1, pages 33-57.
Crossref
Crossref
Ngoc‐Anh Le, Joanne E. Tomassini, Andrew M. Tershakovec, David R. Neff & Peter W. F. Wilson. (2015) Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid‐Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease. Journal of the American Heart Association 4:10.
Crossref
Crossref
Che C. Colpitts, Eloi R. Verrier & Thomas F. Baumert. (2015) Targeting Viral Entry for Treatment of Hepatitis B and C Virus Infections. ACS Infectious Diseases 1:9, pages 420-427.
Crossref
Crossref
Alvaro Cerda, Alice Cristina Rodrigues, Camila Alves, Fabiana Dalla Vecchia Genvigir, Cristina Moreno Fajardo, Egidio Lima Dorea, Maria Cecilia Gusukuma, Gelba Almeida Pinto, Mario Hiroyuki Hirata & Rosario Dominguez Crespo Hirata. (2015) Modulation of Adhesion Molecules by Cholesterol-Lowering Therapy in Mononuclear Cells from Hypercholesterolemic Patients. Cardiovascular Therapeutics 33:4, pages 168-176.
Crossref
Crossref
Harold E. Bays, Erluo Chen, Joanne E. Tomassini, Gail McPeters, Adam B. Polis & Joseph Triscari. (2015) Fixed-dose combination ezetimibe+atorvastatin lowers LDL-C equivalent to co-administered components in randomized trials: use of a dose-response model. Fundamental & Clinical Pharmacology 29:2, pages 209-218.
Crossref
Crossref
Robert Krysiak, Beata Kowalska, Witold Żmuda & Bogusław Okopień. (2015) The effect of ezetimibe-statin combination on steroid hormone production in men with coronary artery disease and low cholesterol levels. Pharmacological Reports 67:2, pages 305-309.
Crossref
Crossref
Eli M Roth & James M McKenney. (2015) ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks. Future Cardiology 11:1, pages 27-37.
Crossref
Crossref
Yan Zhang, Jun Liu, Sha Li, Rui-Xia Xu, Jing Sun & Jian-Jun Li. (2014) Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats. Lipids in Health and Disease 13:1.
Crossref
Crossref
Alberico L. Catapano, Michel Farnier, JoAnne M. Foody, Peter P. Toth, Joanne E. Tomassini, Philippe Brudi & Andrew M. Tershakovec. (2014) Combination therapy in dyslipidemia: Where are we now?. Atherosclerosis 237:1, pages 319-335.
Crossref
Crossref
Koen Vercauteren, Ahmed Atef Mesalam, Geert Leroux-Roels & Philip Meuleman. (2014) Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization. World Journal of Gastroenterology 20:43, pages 15975.
Crossref
Crossref
Alfred Wong. (2014) Chemical and microbiological considerations of phytosterols and their relative efficacies in functional foods for the lowering of serum cholesterol levels in humans: A review. Journal of Functional Foods 6, pages 60-72.
Crossref
Crossref
Harold Bays. 2014. Lipoproteins in Diabetes Mellitus. Lipoproteins in Diabetes Mellitus
415
433
.
Gisa Gerold & Thomas Pietschmann. (2013) Opportunities and Risks of Host-targeting Antiviral Strategies for Hepatitis C. Current Hepatitis Reports 12:4, pages 200-213.
Crossref
Crossref
Michael H. Davidson, Jason Voogt, Jayraz Luchoomun, Julie Decaris, Salena Killion, Drina Boban, Alexander Glass, Hussein Mohammad, Yun Lu, Deona Villegas, Richard Neese, Marc Hellerstein, David Neff, Thomas Musliner, Joanne E. Tomassini & Scott Turner. (2013) Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans. Atherosclerosis 230:2, pages 322-329.
Crossref
Crossref
Mariëtte Y.M. van der Wulp, Henkjan J. Verkade & Albert K. Groen. (2013) Regulation of cholesterol homeostasis. Molecular and Cellular Endocrinology 368:1-2, pages 1-16.
Crossref
Crossref
Jan Westerink, John E. Deanfield, Ben P. Imholz, Wilko Spiering, Dick C. Basart, Blai Coll, John J.P. Kastelein & Frank L.J. Visseren. (2013) High-dose statin monotherapy versus low-dose statin/ezetimibe combination on fasting and postprandial lipids and endothelial function in obese patients with the metabolic syndrome: The PANACEA study. Atherosclerosis 227:1, pages 118-124.
Crossref
Crossref
Joe M. Chehade, Margaret Gladysz & Arshag D. Mooradian. (2013) Dyslipidemia in Type 2 Diabetes: Prevalence, Pathophysiology, and Management. Drugs 73:4, pages 327-339.
Crossref
Crossref
Laura Trapani. (2013) New compounds able to control hepatic cholesterol metabolism: Is it possible to avoid statin treatment in aged people?. World Journal of Hepatology 5:12, pages 676.
Crossref
Crossref
Jonathan Santas, Rafael Codony & Magda Rafecas. 2013. Natural Products. Natural Products
3437
3464
.
Chih-Chieh Yu, Wen-Ter Lai, Kuang-Chung Shih, Tsung-Hsien Lin, Chieh-Hua Lu, Hung-Jen Lai, Mary E Hanson & Juey-Jen Hwang. (2012) Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trial. BMC Research Notes 5:1.
Crossref
Crossref
Paul Kah Hing Ling, Fernando Civeira, Andrei Gheorghe Dan, Mary E Hanson, Rachid Massaad, Celine Le Bailly De Tilleghem, Christopher Milardo & Joseph Triscari. (2012) Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study. Lipids in Health and Disease 11:1.
Crossref
Crossref
Kirsi Laitinen & Helena Gylling. (2012) Dose-dependent LDL-cholesterol lowering effect by plant stanol ester consumption: clinical evidence. Lipids in Health and Disease 11:1.
Crossref
Crossref
Hiroyuki Takase, Yasuaki Dohi, Tateo Okado, Tomomi Hashimoto, Yoshie Goto & Genjiro Kimura. (2012) Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomised controlled study. European Journal of Clinical Investigation 42:12, pages 1287-1294.
Crossref
Crossref
X. Hu, K. R. Steffensen, Z.‐Y. Jiang, P. Parini, J.‐Å. Gustafsson, M. Gåfvels & G. Eggertsen. (2012) LXRβ activation increases intestinal cholesterol absorption, leading to an atherogenic lipoprotein profile. Journal of Internal Medicine 272:5, pages 452-464.
Crossref
Crossref
Takamitsu Nakamura, Mitsumasa Hirano, Yoshinobu Kitta, Daisuke Fujioka, Yukio Saito, Ken-ichi Kawabata, Jun-ei Obata, Yosuke Watanabe, Kazuhiro Watanabe & Kiyotaka Kugiyama. (2012) A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy. Journal of Cardiology 60:1, pages 12-17.
Crossref
Crossref
Koen Vercauteren, Geert Leroux-Roels & Philip Meuleman. (2012) Blocking HCV entry as potential antiviral therapy. Future Virology 7:6, pages 547-561.
Crossref
Crossref
Robert Krysiak, Witold Zmuda & Bogusław Okopień. (2012) The effect of ezetimibe and simvastatin on hemostasis in patients with isolated hypercholesterolemia. Fundamental & Clinical Pharmacology 26:3, pages 424-431.
Crossref
Crossref
Ana Maria Lottenberg, Renata P.A. Bombo, Angela Ilha, Valeria Sutti Nunes, Edna R. Nakandakare & Eder C.R. Quintão. (2012) Do clinical and experimental investigations support an antiatherogenic role for dietary phytosterols/stanols?. IUBMB Life 64:4, pages 296-306.
Crossref
Crossref
Peter P. Toth, Christie M. Ballantyne, Michael H. Davidson, Joanne E. Tomassini, Dena Rosen Ramey, David Neff, Andrew M. Tershakovec, X. Henry Hu & Kaan Tunceli. (2012) Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction. Journal of Clinical Lipidology 6:2, pages 180-191.
Crossref
Crossref
N Moghadasian & Mohammed EskinRgia Othman & Mohammed Moghadasian. 2012. Functional Foods and Cardiovascular Disease. Functional Foods and Cardiovascular Disease
111
140
.
Bruno SainzJrJr, Naina Barretto, Danyelle N Martin, Nobuhiko Hiraga, Michio Imamura, Snawar Hussain, Katherine A Marsh, Xuemei Yu, Kazuaki Chayama, Waddah A Alrefai & Susan L Uprichard. (2012) Identification of the Niemann-Pick C1–like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nature Medicine 18:2, pages 281-285.
Crossref
Crossref
Laura Trapani. (2012) Regulation and deregulation of cholesterol homeostasis: The liver as a metabolic “power station”. World Journal of Hepatology 4:6, pages 184.
Crossref
Crossref
Jesús Millán Núñez-Cortés, Eduardo Alegría, Luis Alvarez-Sala Walther, Juan Ascaso Gimilio, Carlos Lahoz Rallo, Teresa Mantilla Morató, José M. Mostaza Prieto, Juan Pedro-Botet Montoya & Xavier Pintó Sala. (2012) Documento Abordaje de la dislipidemia. Sociedad Española de Arteriosclerosis (parte II). Clínica e Investigación en Arteriosclerosis 24:1, pages 40-52.
Crossref
Crossref
Daniel Duprez. 2012. Coronary Heart Disease. Coronary Heart Disease
497
508
.
Harry R. DavisJrJr, Andrew M. Tershakovec, Joanne E. Tomassini & Thomas Musliner. (2011) Intestinal sterol transporters and cholesterol absorption inhibition. Current Opinion in Lipidology 22:6, pages 467-478.
Crossref
Crossref
Laura Trapani, Marco Segatto, Paolo Ascenzi & Valentina Pallottini. (2011) Potential role of nonstatin cholesterol lowering agents. IUBMB Life 63:11, pages 964-971.
Crossref
Crossref
D. S. H. Bell, F. Al Badarin & J. H. O’KeefeJrJr. (2011) Therapies for diabetic dyslipidaemia. Diabetes, Obesity and Metabolism 13:4, pages 313-325.
Crossref
Crossref
Robert Krysiak & Boguslaw Okopien. (2011) The Effect of Ezetimibe and Simvastatin on Monocyte Cytokine Release in Patients With Isolated Hypercholesterolemia. Journal of Cardiovascular Pharmacology 57:4, pages 505-512.
Crossref
Crossref
Harry R. DavisJr.Jr., Robert S. Lowe & David R. Neff. (2011) Effects of ezetimibe on atherosclerosis in preclinical models. Atherosclerosis 215:2, pages 266-278.
Crossref
Crossref
Christoph H Saely, Veronika Drexel, Alexander Vonbank & Heinz Drexel. (2011) Lipid management in Type 2 diabetes: the case for combination therapy?. Therapy 8:2, pages 129-141.
Crossref
Crossref
Álvaro Cerda, Fabiana Dalla Vecchia Genvigir, Alice Cristina Rodrigues, Maria Alice Vieira Willrich, Egidio Lima Dorea, Márcia Martins Silveira Bernik, Simone Sorkin Arazi, Raquel de Oliveira, Mario Hiroyuki Hirata & Rosario Dominguez Crespo Hirata. (2011) Influence of Polymorphisms and Cholesterol-Lowering Treatment on SCARB1 mRNA Expression. Journal of Atherosclerosis and Thrombosis 18:8, pages 640-651.
Crossref
Crossref
Finn Akerström & Luis Rodríguez-Padial. (2011) The IMPROVE-IT trial: current status and potential clinical implications of ezetimibe. Clinical Investigation 1:1, pages 137-144.
Crossref
Crossref
Fabiana D.V. Genvigir, Alice C. Rodrigues, Alvaro Cerda, Mario H. Hirata, Rui Curi & Rosario D.C. Hirata. (2011) ABCA1 and ABCG1 expressions are regulated by statins and ezetimibe in Caco-2 cells. Drug Metabolism and Drug Interactions 26:1.
Crossref
Crossref
Jure Ačimovič, Tina Korošec, Matej Seliškar, Ingemar Bjorkhem, Katalin Monostory, Pal Szabo, Jean-Marc Pascussi, Ales Belič, Uroš Urleb, Darko Kocjan & Damjana Rozman. (2011)
Inhibition of Human Sterol Δ
7
-Reductase and Other Postlanosterol Enzymes by LK-980, a Novel Inhibitor of Cholesterol Synthesis
. Drug Metabolism and Disposition 39:1, pages 39-46.
Crossref
Crossref
Carlo M Rotella, Augusto Zaninelli, Cristina Le Grazie, Mary E Hanson & Gian Franco Gensini. (2010) Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes. Lipids in Health and Disease 9:1.
Crossref
Crossref
Stephen D. Turley, Mark A. Valasek, Joyce J. Repa & John M. Dietschy. (2010) Multiple mechanisms limit the accumulation of unesterified cholesterol in the small intestine of mice deficient in both ACAT2 and ABCA1. American Journal of Physiology-Gastrointestinal and Liver Physiology 299:5, pages G1012-G1022.
Crossref
Crossref
R. Mangat, S. Warnakula, Y. Wang, J.C. Russell, R. Uwiera, D.F. Vine & S.D. Proctor. (2010) Model of intestinal chylomicron over-production and Ezetimibe treatment: Impact on the retention of cholesterol in arterial vessels. Atherosclerosis Supplements 11:1, pages 17-24.
Crossref
Crossref
Wolfram Haller, Khalid Sharif, Alastair JW Millar, Rachel M Brown & Patrick J McKiernan. (2010) Gallbladder Dysfunction in Cholesterol Ester Storage Disease. Journal of Pediatric Gastroenterology & Nutrition 50:5, pages 555-558.
Crossref
Crossref
Todd C. Rideout, Scott V. Harding, Christopher P.F. Marinangeli & Peter J.H. Jones. (2010) Combination drug–diet therapies for dyslipidemia. Translational Research 155:5, pages 220-227.
Crossref
Crossref
T. Stojakovic, A. De Campo, H. Scharnagl, H. Sourij, I. Schmölzer, T. C. Wascher & W. März. (2010) Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events. European Journal of Clinical Investigation 40:3, pages 187-194.
Crossref
Crossref
Almasa Bass, Alan L Hinderliter & Craig R Lee. (2009) The Impact of Ezetimibe on Endothelial Function and Other Markers of Cardiovascular Risk. Annals of Pharmacotherapy 43:12, pages 2021-2030.
Crossref
Crossref
Ildikó Kasza, Zoltán Hegyi, Katalin Szabó, Hajnalka Andrikovics, Katalin Német, András Váradi, Balázs Sarkadi & László Homolya. (2009) Model system for the analysis of cell surface expression of human ABCA1. BMC Cell Biology 10:1.
Crossref
Crossref
Heinz Drexel. (2009) Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients?. Fundamental & Clinical Pharmacology 23:6, pages 687-692.
Crossref
Crossref
Yajun Cheng, Fuli Liu, Jun Wu, Yao Zhang, Åke Nilsson & Rui‐Dong Duan. (2009) Ezetimibe Inhibits Expression of Acid Sphingomyelinase in Liver and Intestine. Lipids 44:10, pages 897-906.
Crossref
Crossref
Meifania Chen & Maja Hadzic. (2009) Lipoprotein ontology as a functional knowledge base. Lipoprotein ontology as a functional knowledge base.
Manfredi Rizzo, Giovam Battista Rini, Giatgen A. Spinas & Kaspar Berneis. (2009) The effects of ezetimibe on LDL-cholesterol: Quantitative or qualitative changes?. Atherosclerosis 204:2, pages 330-333.
Crossref
Crossref
Ebru Uçaktürk, Nuran Özaltin & Baris Kaya. (2009) Quantitative analysis of ezetimibe in human plasma by gas chromatography-mass spectrometry. Journal of Separation Science 32:11, pages 1868-1874.
Crossref
Crossref
Firas J. Al Badarin, Iftikhar J. Kullo, Stephen L. Kopecky & Randal J. Thomas. (2009) Impact of Ezetimibe on Atherosclerosis: Is the Jury Still Out?. Mayo Clinic Proceedings 84:4, pages 353-361.
Crossref
Crossref
Firas J. Al Badarin, Iftikhar J. Kullo, Stephen L. Kopecky & Randal J. Thomas. (2009) Impact of Ezetimibe on Atherosclerosis: Is the Jury Still Out?. Mayo Clinic Proceedings 84:4, pages 353-361.
Crossref
Crossref
Katalin Monostory, Jean-Marc Pascussi, Pál Szabó, Manna Temesvári, Krisztina Köhalmy, Jure Acimovic, Darko Kocjan, Drago Kuzman, Britta Wilzewski, Rita Bernhardt, László Kóbori & Damjana Rozman. (2009) Drug Interaction Potential of 2-((3,4-Dichlorophenethyl)(propyl)amino)-1-(pyridin-3-yl)ethanol (LK-935), the Novel Nonstatin-Type Cholesterol-Lowering Agent. Drug Metabolism and Disposition 37:2, pages 375-385.
Crossref
Crossref
George Steiner. (2008) Lipid lowering in the patients with prediabetes/metabolic syndrome: what is the evidence?. Current Opinion in Lipidology 19:6, pages 585-591.
Crossref
Crossref
Scott E. Conard, Harold E. Bays, Lawrence A. Leiter, Steven R. Bird, Joseph Rubino, Robert S. Lowe, Joanne E. Tomassini & Andrew M. Tershakovec. (2008) Efficacy and Safety of Ezetimibe Added on to Atorvastatin (20 mg) Versus Uptitration of Atorvastatin (to 40 mg) in Hypercholesterolemic Patients at Moderately High Risk for Coronary Heart Disease††Conflicts of interest: Dr. Conard served as a consultant and advisor for Merck & Company and Merck/Schering-Plough. Dr. Bays received research grants from Amylin, San Diego, California, Amgen, Thousand Oaks, California, J&J, Langhorne, Pennsylvania, Aegerion, Bridgewater, New Jersey, Abbott, Chicago, Illinois, Arena Pharmaceuticals, San Diego, California, GlaxoSmithKline (Glaxo), London, UK, Hoffmann LaRoche, Nutley, New Jersey, Merck, Whitehouse Station, New Jersey, MSP, Kenilworth, New Jersey, Metabolex, San Jose, California, Schering-Plough, Kenilworth, New Jersey, Orexigen, San Diego, California, Reliant, Liberty Corner, New Jersey, Sciele, Atlanta, Georgia, Takeda, Osaka, Japan, TAP, Lake Forest, Illinois, and Vivus, Mountain View, California; received speakers' honoraria from Abbott, Daiichi Sankyo, Tokyo, Japan, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; received honoraria from Abbott, AstraZeneca, London, UK (Wilmington, Delaware, US Headquarters), Daiichi Sankyo, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; and served as a consultant and advisor for Abbott, GlaxoSmithKline, Metabolex, San Jose, California, Reliant, Takeda, AstraZeneca, and Essentialis, Carlsbad, California. Dr. Leiter received grants and speakers' honoraria from and served as a consultant and advisor for AstraZeneca, Merck & Company, Merck/Schering-Plough, and Pfizer, New York, New York. Mr. Bird, Mr. Rubino, and Drs. Lowe, Tomassini, and Tershakovec are employees of Merck & Company and may own stock and/or hold stock options in the company.. The American Journal of Cardiology 102:11, pages 1489-1494.
Crossref
Crossref
Tuomo NieminenMika Kähönen, Leena E Viiri, Paula Grönroos & Terho Lehtimäki. (2008) Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease. Pharmacogenomics 9:10, pages 1475-1486.
Crossref
Crossref
Mark A. Valasek, Joyce J. Repa, Gang Quan, John M. Dietschy & Stephen D. Turley. (2008) Inhibiting intestinal NPC1L1 activity prevents diet-induced increase in biliary cholesterol in Golden Syrian hamsters. American Journal of Physiology-Gastrointestinal and Liver Physiology 295:4, pages G813-G822.
Crossref
Crossref
Richard A Krasuski. (2008) Therapy and clinical trials. Current Opinion in Lipidology 19:5, pages 550-551.
Crossref
Crossref